<DOC>
	<DOCNO>NCT01692366</DOCNO>
	<brief_summary>Primary Objective : - To evaluate efficacy daily oral dos 300 mg , 400 mg , 500 mg SAR302503 combine response rate define â‰¥35 % reduction spleen volume determine magnetic resonance imaging ( MRI compute tomography scan [ CT ] patient contraindication MRI ) . Secondary Objectives : - To evaluate safety SAR302503 pool ( 300 , 400 , 500mg ) individual dose population . - To evaluate pharmacokinetics ( PK ) SAR302503 single repeat-dose . - To evaluate effect Myelofibrosis ( MF ) -associated symptom ( Key MF symptom ) measure modified Myelofibrosis Symptom Assessment Form ( MFSAF ) . - To evaluate durability splenic response . - To evaluate effect SAR302503 bone marrow regard change reticulin fibrosis .</brief_summary>
	<brief_title>Phase 2 Study Japanese Patients With Intermediate-2 High Risk Primary Myelofibrosis , Post-Polycythemia Vera Myelofibrosis , Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly</brief_title>
	<detailed_description>The duration study individual patient include period assess eligibility ( screen period 28 day ) , follow treatment period least 1 cycle ( 28 day ) study treatment , end-of-treatment visit least 30 day follow last administration study drug . However , treatment may continue patient derive benefit unacceptable toxicity meet study withdrawal criterion .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Splenomegaly</mesh_term>
	<criteria>Inclusion criterion : Diagnosis primary postpolycythemia vera postessential thrombocythemia myelofibrosis Myelofibrosis classify highrisk intermediaterisk level 2 Enlarged spleen , palpable least 5 cm costal margin Active symptom myelofibrosis At least 20 year age Eastern Collaborative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 study entry Absence active malignancy myelofibrosis Written inform consent participate . Exclusion criterion : Splenectomy . Any recent chemotherapy ( eg , hydroxyurea ) , immunomodulatory drug therapy ( eg , thalidomide , interferonalpha ) , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , growth factor treatment ( eg , erythropoietin ) , hormone ( eg , androgen , danazol ) within 14 day prior initiation study drug . Major surgery therapy within 28 day radiation include spleen radiation within 6 month prior initiation study drug . Concomitant treatment use pharmaceutical herbal agent know moderate severe inhibitor inducer CYP3A4 . Active acute infection require antibiotic . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . Participation study investigational agent ( drug , biologic , device ) within 30 day , unless nontreatment phase . Prior treatment JAK 2 Inhibitor . Treatment aspirin dos &gt; 150 mg/day Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . Pregnant lactate female . Once lactating female stop participate study , restart feed baby . Women childbearing potential , unless use effective contraception study drug . Otherwise patient must postmenopausal ( least 1 year last menstruation without medical reason ) , surgically sterile . Known active ( acute chronic ) Hepatitis A , B , C ; hepatitis B C carrier . Prior history chronic liver disease ( eg , chronic alcoholic liver disease , autoimmune hepatitis , sclerosing cholangitis , primary biliary cirrhosis , hemachromatosis , nonalcoholic steatohepatitis [ NASH ] ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>